Intellia Therapeutics, Inc.(NTLA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Intellia Therapeutics, Inc. (NTLA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores NTLA at 19.9/100 on a 32-signal composite quality model, placing it at rank #2,783 of 2,960 stocks — the bottom half of the AI-ranked universe. NTLA scores in the top quartile across institutional flow (99.1). Areas of concern include free cash flow (2.5) and profitability (2.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 2.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Intellia Therapeutics, Inc. reports quarterly revenue of $7.7M, net income of $-106.6M, free cash flow of $-84.9M. Top institutional holders of NTLA by reported 13-F value include ARK Investment Management, BlackRock, STATE STREET, based on the most recent SEC filings. NTLA trades on the Nasdaq exchange and files with the SEC under CIK 1652130. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NTLA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Intellia Therapeutics, Inc. directly from SEC EDGAR.